Table 3.
Demographics and HIV-Related Clinical Characteristics of Participants Receiving Early Treatment by ART Class (Results From Data Set B)
| All (n = 299) | NNRTI (n = 72) | PI (n = 124) | INSTI (n = 95) | P Valuea | |
|---|---|---|---|---|---|
| Age at ART initiation, median (IQR), y | 34.6 (27.7 to 42.0) | 34.4 (28.3 to 42.9) | 36.1 (28.8 to 41.9) | 31.8 (26.3 to 40.8) | .152 |
| Race | .032 | ||||
| White, No. (%) | 249 (83.3) | 64 (88.9) | 108 (87.1) | 69 (72.6) | |
| Black, No. (%) | 16 (5.4) | 3 (4.2) | 6 (4.8) | 7 (7.4) | |
| Hispanic ethnicity, No. (%) | 95 (31.8) | 19 (26.4) | 22 (17.7) | 51 (53.7) | <.001 |
| Year of ART initiation, median (IQR) | 2005 (2003 to 2014) | 2003 (2002 to 2005) | 2004 (2002 to 2010) | 2016 (2015 to 2017) | <.001 |
| Weight at ART initiation, median (IQR), kg | 76.2 (68.0 to 86.0) | 76.2 (68.5 to 84.6) | 76.0 (68.9 to 84.1) | 74.4 (66.7 to 88.8) | .939 |
| CD4 count at ART initiation, median (IQR), cells/μL | 499 (366 to 674) | 492 (359 to 674) | 489 (355 to 619) | 541 (404 to 682) | .109 |
| CD4 count at 24 wk after ART initiation, median (IQR), cells/μL | 696 (525 to 865) | 574 (470 to 752) | 709 (549 to 862) | 753 (610 to 916) | <.001 |
| Log HIV RNA at ART initiation, median (IQR), copies/mL | 5.0 (4.5 to 5.6) | 4.8 (4.5 to 5.3) | 5.1 (4.7 to 5.8) | 5.0 (4.3 to 5.8) | .014 |
| Viral suppressed at 24 wk after ART initiation, No. (%) | 281 (96.3) | 69 (95.8) | 119 (96.0) | 93 (97.9) | .567 |
| Time from enrollment to ART initiation, median (IQR), wk | 3.9 (2.1 to 13.7) | 14.5 (7.1 to 32.1) | 3.4 (2.1 to 10.9) | 2.1 (2.0 to 4.0) | <.001 |
| Time of initial ART use, median (IQR), wk | 84.1 (48.6 to 126.0) | 91.3 (54.6 to 146.2) | 78.1 (48.9 to 106.3) | 86.6 (45.7 to 136.4) | .192 |
| Main NRTI component | <.001 | ||||
| TDF, No. (%) | 178 (59.5) | 51 (70.8) | 78 (62.9) | 43 (45.3) | |
| TAF, No. (%) | 49 (16.4) | 0 (0.0) | 0 (0.0) | 49 (51.6) | |
| Other NRTI, No. (%) | 72 (24.1) | 21 (29.2) | 46 (37.1) | 3 (3.2) |
Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
aEight individuals who received NRTI only were not included for analysis.